Viela Bio, a late-stage biotech developing therapies for autoimmune diseases, filed on Thursday with the SEC to raise up to $150 million in an initial public offering.
The Gaithersburg, MD-based company was founded in 2017 and booked $20 million in license revenue for the 12 months ended June 30, 2019. It plans to list on the Nasdaq under the symbol VIE. Viela Bio filed confidentially on June 17, 2019. Goldman Sachs, Morgan Stanley, and Cowen are the joint bookrunners on the deal. No pricing terms were disclosed.
